Author of

• 12262

  +

  O20 - Staging and Advanced Disease (ID 102)

  • Event: WCLC 2013
  • Type: Oral Abstract Session
  • Track: Surgery
  • Presentations: 1
  • Moderators:P.A. Ugalde, S. Yendamuri
  • Coordinates: 10/29/2013, 16:15 - 17:45, Parkside 110 A+B, Level 1

  • 12269

    +

    O20.07 - Local therapy for limited distant metastasis in patients with completely resected NSCLC (ID 1262)

    17:20 - 17:30  |  Author(s): K. Inoue
    • Abstract
    • Presentation
    • Slides

    Background
    In general, distant metastasis is regarded as an incurable systemic disease. Therefore, local therapies including metastasectomy or radiotherapy are rarely applied, and the treatment goals are disease control using chemotherapy or palliation. There are, however, several reports in which local therapy can contribute to long-term survival in patients with metastatic disease, especially for brain metastasis or adrenal metastasis in patients with NSCLC.

    Methods
    Between 1986 and 2009, among 1548 patients who underwent surgical resection for NSCLC in our institution, we identified 405 patients who experienced recurrence after R0 resection, without history of other malignancy, and detailed recurrence information available. We investigated the recurrent mode, number of metastatic focus and organ, treatment for metastasis, and prognosis.

    Results
    Among 405 patients, 245 patients had distant metastasis without local recurrence, 115 had local recurrence, and 45 had both local and distant metastasis. We focused on the 245 patients with distant metastasis without local recurrence, including 215 patients who had only single organ metastasis and 93 patients who had only solitary metastasis. The treatments for distant metastasis and the 5-year survival rates were shown in the Table 1. The number of organ involved and metastatic focus were significantly associated with prolonged survival. Local therapy were mainly applied for limited metastases, and associated with higher survival rates. The number of patients and the 5-year survival rates according to the metastatic organ in patients with solitary metastasis are shown in Table 2. Other metastatic organ included soft tissue in 3 patients, kidney in 3, and trachea, intestine, and abdominal lymph node in 1.Finally, 6 patients survived more than 5 years with disease-free status; these included 2 brains, 2 lungs, 1 bone, and 1 subcutaneous metastasis.

    Table 1

    	Multiple organ		Single organ		Multiple		Single
    Treatment	Number of pts	5y OS (%)	Number of pts	5y OS (%)	Number of pts	5y OS (%)	Number of pts	5y OS (%)
    BSC	8	0	48	6.4	43	7.1	5	0
    Chemo Tx	3	0	32	16.3	30	17.7	2	0
    Radio Tx	19	5.7	101	11.8	43	0	58	21.4
    Surgery	0	-	34	38.0	6	66.7	28	33.4
    Total	30	3.5	215	15.2	122	8.9	93	23.3

    Table 2

    Organ	Number of pts	5y OS (%)
    Brain	36	19.2
    Bone	24	16.7
    Lung	18	32.4
    Adrenal gland	6	0
    Other	9	55.6

    Conclusion
    Prolonged survival can be achieved using local therapy in patients with limited distant metastasis irrespective of metastatic organ.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.